Monday, October 9, 2000
Facing a crowded market with an uncertain intellectual property
situation, Affymetrix Inc. continues to burrow deeper into its core array space, but now
may be hedging its bets by taking a stake in downstream discovery and development.
By acquiring a bioinformatics company last week, AFFX plans to design
better and more customized arrays, especially chips that will be used for
pharmacogenomics. At the same time, the company is creating a spinoff to use genetic
information to identify drug targets, and possibly develop therapeutics.